2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Carcinoma, Hepatocellular
8
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Liver Malignancy
1
Hepatic Malignancies
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Interventions
lutetium Lu 177 dotatate
40
Everolimus
35
Magnetic Resonance Spectroscopy
15
lanreotide
14
gallium Ga 68 dotatate
13
Temozolomide
13
Octreotide
12
Nivolumab
12
pembrolizumab
11
Capecitabine
11
surufatinib
10
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Sunitinib
8
Specimen Handling
7
Carboplatin
7
telotristat ethyl
6
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Lutetium-177
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Ipilimumab
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Yttrium-90
×
Clear all
NCT04339036
2026-06-04
CapTemY90
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
70 enrolled
NCT04790708
2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA
Unknown
250 enrolled